Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Payables (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Payables for 11 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Payables changed N/A to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $10.0 million for FY2025, N/A changed from the prior year.
  • Payables for Q4 2025 was $10.0 million at Crescent Biopharma, up from $89000.0 in the prior quarter.
  • The five-year high for Payables was $10.0 million in Q4 2025, with the low at $89000.0 in Q3 2025.
  • Average Payables over 5 years is $1.7 million, with a median of $950763.0 recorded in 2024.
  • Peak annual rise in Payables hit 446.93% in 2025, while the deepest fall reached 86.15% in 2025.
  • Over 5 years, Payables stood at $2.1 million in 2021, then crashed by 53.97% to $970191.0 in 2022, then decreased by 10.52% to $868115.0 in 2023, then plummeted by 32.98% to $581794.0 in 2024, then surged by 1618.31% to $10.0 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $10.0 million, $89000.0, and $5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.